SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-14 |
| Reported value | $865,529,222 |
| Positions | 27 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| GH RESEARCH PLC | GHRS | ORDINARY SHARES | $356,517,181 | 13,263,288 |
| CULLINAN THERAPEUTICS INC | CGEM | COM | $163,225,335 | 8,963,500 |
| STOKE THERAPEUTICS INC | STOK | COM | $132,136,579 | 4,038,404 |
| AGIOS PHARMACEUTICALS INC | AGIO | COM | $126,505,652 | 3,408,937 |
| C4 THERAPEUTICS INC | CCCC | COM STK | $34,215,647 | 7,326,691 |
| KORRO BIO INC | KRRO | COM | $20,274,741 | 1,538,296 |
| TSCAN THERAPEUTICS INC | TCRX | COM | $7,859,567 | 8,019,148 |
| PRECISION BIOSCIENCES INC | DTIL | COM NEW | $7,470,663 | 950,466 |
| NEUPHORIA THERAPEUTICS INC | NEUP | COM | $3,825,183 | 875,328 |
| PASSAGE BIO INC | PASG | COM NEW | $3,287,942 | 673,759 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.